Ya-Zun Liu Liu

Dr. Ya-Zun Liu Liu


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2023 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
YLYa-Zun Liu Liu
Ya-Zun Liu Liu
LXLan Xu
Lan Xu
XPXiang Piao
Xiang Piao
HLHan Li
Han Li
LSLi Shi
Li Shi
LZLiwei Zhong
Liwei Zhong
To describe the epidemiological, clinical, and household transmission characteristics of pediatric COVID-19 cases in Shanghai, China. Pediatric patients with COVID-19 hospitalized in Shanghai from March-May 2022 were enrolled in this retrospective, multicenter cohort study. The symptoms and the risk factors associated with disease severity were analyzed. In total, 2620 cases (age range, 24 days-17 years) were enrolled in this study. Of these, 1011 (38.6%) were asymptomatic, whereas 1415 (54.0%), 190 (7.3%), and 4 (0.2%) patients developed mild, moderate, and severe illnesses, respectively. Household infection rate was negatively correlated with household vaccination coverage. Children aged 0-3 years, those who are unvaccinated, those with underlying diseases, and overweight/obese children had a higher risk of developing moderate to severe disease than children aged 12-17 years, those who were vaccinated, those without any underlying disease, and those with normal weight, respectively (all P <0.05). A prolonged duration of viral shedding was associated with disease severity, presence of underlying diseases, vaccination status, and younger age (all P <0.05). Children aged younger than 3 years who were not eligible for vaccination had a high risk of developing moderate to severe COVID-19 with a prolonged duration of viral shedding. Vaccination could protect children from COVID-19 at the household level.

1 January 2025 in Journal of Immunology Research
Verified
Journal Article
Open access
MLManchen Lu
Manchen Lu
FCFeiyan Cheng
Feiyan Cheng
XZXiaoman Zhao
Xiaoman Zhao
ZWZhuiyue Wang
Zhuiyue Wang
JCJing Chen
Jing Chen
WYWenbo Yao
Wenbo Yao
Asthma is a chronic inflammatory respiratory disease with a distinct circadian rhythm. Common symptoms like cough, wheezing, and dyspnea, are worse at night and in the early morning (around 4 a.m.). The circadian pattern of asthma is intrinsically connected to the body’s internal clock, which regulates a wide range of biological processes via transcription‐translation feedback loop (TTFL). BMAL1 and CLOCK play a central role in the regulatory networks that control metabolism and immune function. When circadian rhythms are disrupted, it can result in metabolic disorders, immune dysfunction, and a worsening of asthma symptoms. A deeper understanding of the mechanisms underlying circadian rhythms may pave the way for innovative asthma treatments. Furthermore, the exploration and application of natural drugs and targeted therapies focusing on circadian rhythm genes show potential as a key approach for future precision treatment of asthma.

7 November 2023 in Iranian Journal of Allergy, Asthma and Immunology
Verified
Journal Article
Closed access
WCWen Cui
Wen Cui
HZHuan Zhou
Huan Zhou
YLYa-Zun Liu Liu
Ya-Zun Liu Liu
YYYan Yang
Yan Yang
YHYi-Zhong Hu
Yi-Zhong Hu
ZXZheng Xue
Zheng Xue
Asthma, characterized by persistent inflammation and increased sensitivity of the airway, is the most common chronic condition among children. Novel, safe, and reliable treatment strategies are the focus of current research on pediatric asthma. Amygdalin, mainly present in bitter almonds, has anti-inflammatory and immunoregulatory potential, but its effect on asthma remains uninvestigated. Here, the impact of amygdalin on the thymic stromal lymphopoietin (TSLP)–dendritic cell (DC)–OX40L axis was investigated. A BALB/c mouse model for allergic asthma was established using the ovalbumin-sensitization method. Amygdalin treatment was administered between days 21 and 27 of the protocol. Cell numbers and hematoxylin and eosin (H&E) staining in bronchoalveolar lavage fluid (BALF) were used to observe the impact of amygdalin on airway inflammation. TSLP, IL-4, IL-5, IL-13, and IFN-γ concentrations were determined via Enzyme-linked immunosorbent assay (ELISA). TSLP, GATA-3, and T-bet proteins were measured using western blotting. Cell-surface receptor expression on DCs (MHC II, CD80, and CD86) was assessed via flow cytometry. OX40L mRNA and protein levels were detected using western blotting and qRT-PCR, respectively. Amygdalin treatment attenuated airway inflammation decreased BALF TSLP levels, inhibited DC maturation, restrained TSLP-induced DC surface marker expression (MHCII, CD80, and CD86), and further decreased OX40L levels in activated DCs. This occurred together with decreased Th2 cytokine levels (IL-4, IL-5, and IL-13) and GATA3 expression, whereas Th1 cytokine (IFN-γ) levels and T-bet expression increased. Amygdalin thus regulates the Th1/Th2 balance through the TSLP–DC–OX40L axis to participate in inflammation development in the airways, providing a basis for potential allergic asthma treatments.